TCT 2015: Abbott's Absorb On Par With Metal DES But Longer Data Still Needed
This article was originally published in Clinica
Executive Summary
Results of the ABSORB III trial, the US pivotal study of Abbott’s Absorb bioresorbable stent, met its primary non-inferiority endpoint, but the ABSORB III investigators concede much longer follow-up in more patients must be collected to know if Absorb improves patient outcomes compared to metal drug-eluting stents (DES).